Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, considers whether DNA repair gene mutations have a predictive or prognostic role in metastatic urothelial carcinoma and the implications for the future.

Published: 14 February 2018

Recent Videos: ASCO GU Conference Coverage

video

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, shares thoughts on the usefulness of the PD-L1 ...

video

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, explains how molecular characterization and bladder subtyping data ...

video

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, tells us about the POUT clinical study presented ...

video

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, discusses whether DNA repair gene mutations have a ...

video

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, elaborates on the role of immunotherapy in patients ...

video

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, offers opinion on the best way to combine ...

Related Videos

video-image

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

video-image

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

video-image

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

video-image

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

video-image

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

video-image

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

video-image

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

video-image

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

video-image

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

video-image

Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018

video-image

Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer

video-image

Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data

video-image

Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer

video-image

William K. Oh, MD, on abiraterone acetate fine particle formulation

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

video-image

Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study

video-image

Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma

video-image

Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer

video-image

Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors

video-image

Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma